Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins

作者：Harris Leanne F; Castro Lopez Vanessa; Hammadi Nissrin; O'Donnell James S; Killard Anthony J^*

来源：Talanta, 2010, 81(4-5): 1725-1730.

DOI：10.1016/j.talanta.2010.03.030

• Anti-FXa assay
• Fluorescence
• Pefafluor FXa
• Unfractionated heparin
• Low molecular weight heparin
• Danaparoid

Fluorogenic assays have many potential advantages over traditional clot-based and chromogenic assays such as the absence of interference from a range of factor deficiencies as well as offering the possibility of assays in platelet rich plasma or whole blood A fluorogenic anti-factor Xa (anti-FXa) assay has been developed for the determination of unfractionated heparin (UFH). low molecular weight heparins (LMWHs), namely enoxaparin and tinzaparin. and the synthetic heparinoid danaparoid, in commercial human pooled plasma The assay was based on the complexation of heparin-spiked plasmas with exogenous FXa at a concentration of 4 nM in the presence of 09 mu M of the fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-4-methylcoumarin acetate (Pefafluor FXa). Pooled plasma samples were spiked with concentrations of anticoagulants in the range 0-1.6 U/mL he assay was capable of the measurement of UFH and danaparoid in the range 0-1 U/ml, and enoxaparin and tinzaparin in the range 0-08 and 0-06 U/ml, respectively Correlation coefficients generated by linear regression of the log/lm data analysis were between 0.93 and 096 for the anticoagulants tested.

• 出版日期2010-6-15